MyFinsight
Home
Blog
About
Contact
Download
Download image
Non Us
$913,100K
(-6.13%↓ Y/Y)
US
$839,200K
(11.33%↑ Y/Y)
Royalty Attributed To
OCREVUS
$317,200K
(9.83%↑ Y/Y)
Biogen's share of pre-tax
profits in the u.s. for...
$94,700K
(13.14%↑ Y/Y)
Other revenues from
anti-cd20 therapeutic...
$7,200K
(26.32%↑ Y/Y)
Contract Manufacturing
And Other Revenue
$237,200K
(-15.98%↓ Y/Y)
Royalty
$9,700K
(-11.82%↓ Y/Y)
Product
$1,752,300K
(1.49%↑ Y/Y)
Revenuesfromanticd20therapeuticprograms
$419,100K
(10.81%↑ Y/Y)
Product And Service
Other
$246,900K
(-15.82%↓ Y/Y)
LEQEMBICollaboration
$59,500K
(80.30%↑ Y/Y)
Total revenue
$2,477,800K
(1.93%↑ Y/Y)
Income before income
tax (benefit)...
$377,700K
(21.37%↑ Y/Y)
Total cost and expense
$2,100,100K
(-0.93%↓ Y/Y)
Net income
attributable to biogen inc
$319,500K
(32.85%↑ Y/Y)
Income tax (benefit)
expense
$58,200K
(-17.68%↓ Y/Y)
Cost of sales,
excluding amortization...
$661,000K
(5.04%↑ Y/Y)
Selling, general and
administrative
$607,300K
(6.08%↑ Y/Y)
Research and development
$539,000K
(24.16%↑ Y/Y)
Amortization and impairment
of acquired...
$136,500K
(22.09%↑ Y/Y)
Collaboration profit
sharing/(loss reimbursement)
$74,200K
(27.71%↑ Y/Y)
Acquired in-process
research and...
$34,000K
(-83.06%↓ Y/Y)
Business combination,
contingent consideration,...
$20,500K
(113.54%↑ Y/Y)
Other (income)
expense, net
-$19,700K
(71.20%↑ Y/Y)
Restructuring charges
$7,900K
(-77.62%↓ Y/Y)
Back
Back
Income Statement
Biogen-svg
source: myfinsight.com
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)